« Return to News | Drug Sponsors

Pharmstandard seeks to acquire Bever Pharmaceutical

Wednesday, August 14, 2013 01:15 PM

Pharmstandard has announced key terms for a possible acquisition of 100% of the share capital of Bever Pharmaceutical. It is expected that Bever will be included in a proposed spin-off of the company's branded over-the-counter business.

Total consideration for the acquisition of Bever is agreed at $590 million and will be funded by the combination of Pharmstandard's shares and GDRs owned by Pharmstandard-Leksredstva to the amount of $542 million and cash of $48 million, which may be financed from external sources. Pharmstandard-Leksredstva currently holds Pharmstandard's shares and GDRs on its balance sheet at approximately $475million.

The company’s rationale for the transaction includes securing a long-term fixed-cost supply of critical active pharmaceutical ingredients for two flagship OTC brands, Arbidol and Aphobazolum, as well as significantly increasing the company's profitability.

Bever is controlled by Bristley Enterprises, owned by Dr. Alexander Shuster, the company's non-executive member of the board of directors.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.